Substituted 1,3-benzothiazepines useful in treating metabolic disorders

602754 Provided are dioxido-phenyl-benzothiazepin derivatives of formula (I), where Q, R1, R2, R3, R4 and X are as defined in the specification. An example of the derivatives is 3-({ [(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]carbonyl} amin...

Full description

Saved in:
Bibliographic Details
Main Authors COWAN DAVID JOHN, WU YULIN, AQUINO CHRISTOPHER JOSEPH, COLLINS JON LOREN
Format Patent
LanguageEnglish
Published 30.05.2014
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:602754 Provided are dioxido-phenyl-benzothiazepin derivatives of formula (I), where Q, R1, R2, R3, R4 and X are as defined in the specification. An example of the derivatives is 3-({ [(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]carbonyl} amino)-2,2-dimethylpropanoic acid. Methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and therapeutic uses of them are further provided. These compounds are suitable for treating metabolic disorders, particularly diabetes mellitus (Type I and Type II) or obesity.
Bibliography:Application Number: NZ20110602754